IL17A and inflammatory bowel disease: Aside from multiple biological explanations, the negative results of IL-17 blockade make one reflect on the pleiotropic and complex molecular pathways underlying IBD, in which the same cytokine potentially possesses both protective and pathogenic effects on mucosal inflammation in different phases of disease, or within different compartments of the innate/acquired immune systems (Pagnini et al., 2010).